Head-To-Head Comparison: Medicure (OTCMKTS:MCUJF) versus Qualigen Therapeutics (NASDAQ:QLGN)

Medicure (OTCMKTS:MCUJF) and Qualigen Therapeutics (NASDAQ:QLGN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Earnings & Valuation

This table compares Medicure and Qualigen Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medicure	$15.99 million	0.53	-$760,000.00	($0.24)	-3.35
Qualigen Therapeutics	N/A	N/A	-$6.26 million	($7.50)	-0.17

Medicure has higher revenue and earnings than Qualigen Therapeutics. Medicure is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Medicure has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Comparatively, Qualigen Therapeutics has a beta of 0.24, meaning that its share price is 76% less volatile than the S&P 500.

Profitability

This table compares Medicure and Qualigen Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Medicure	-13.10%	-17.91%	-11.95%
Qualigen Therapeutics	N/A	N/A	-202.16%

Analyst Ratings

This is a breakdown of current ratings for Medicure and Qualigen Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medicure	0	0	0	0	0.00
Qualigen Therapeutics	1	0	0	0	1.00

Institutional and Insider Ownership

3.2% of Qualigen Therapeutics shares are held by institutional investors. 12.9% of Medicure shares are held by insiders. Comparatively, 1.8% of Qualigen Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Medicure beats Qualigen Therapeutics on 6 of the 11 factors compared between the two stocks.

About Medicure

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.

About Qualigen Therapeutics

Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.